

08 December 2023

## **Biological treatments for Gastric Oesophageal and Ovarian Cancer**

I have a freedom of information request regarding the treatment of certain types of cancer. Could you please answer the following questions?

**Q1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:**

- **CAPOX (Capecitabine with Oxaliplatin)**
  - no patients on regimen
- **FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)**
  - no patients on regimen
- **Lonsurf (Trifluridine - tipiracil)**
  - no patients on regimen
- **Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)**
  - Nivolumab OMDG Folfox OG - <5
- **Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)**
  - no patients on regimen
- **Any other systemic anti-cancer therapy**
  - CX Gastric – <5, CX&Trazimera (OG) - 8, FLOT Gastric – 32, Nivolumab CX (OG) – <5, Nivolumab Gastric – <5, IMDG Folfiri Gastric – <5, OX (OG) – 6 OX&Trazimera (OG) – 7, OMDG FOLFOX (OG) – <5, Pembrolizumab CX (OG) – <5, Pembrolizumab OX (OG) – 5,
- **Palliative care only**
  - not recorded

**Q2. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:**

- **Nivolumab monotherapy or combination with Ipilimumab**
  - 10
- **Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)**
  - <5
- **Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)**
  - no patients on regimen

**08 December 2023**

- **Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)**
  - no patients on regimen
- **Any other systemic anti-cancer therapy**
  - CX - 8, CX&XRT – <5, Carboplatin – <5, CarboX&XRT – <5, Docexatel – <5, Etoposide&Carbo – <5, IMDG Folfiri - 6, Paclitaxel&Carboplatin AUC5 – <5, Carboplain AUC1.5&XRT – <5, Cisplatin&XRT – <5, Paclitaxel&Carboplatin - 13
- **Palliative care only**
  - not recorded

**Q3. How many patients were treated in the past 3 months for ovarian cancer (any stage) with:**

- **Paclitaxel in combination with a platinum-based compound**
  - 45
- **Platinum-based therapy alone (cisplatin or carboplatin)**
  - 27
- **Bevacizumab in combination with paclitaxel and carboplatin**
  - Bevac + Paclitaxel 6
- **Olaparib**
  - <5
- **Olaparib + Bevacizumab**
  - <5
- **Niraparib**
  - 5
- **Rucaparib**
  - <5

**Q4. If data for HRD (homologous recombination deficiency) testing is available, please provide how many HRD positive ovarian cancer patients were treated in the last 3 months with:**

- **Olaparib**
- **Olaparib + Bevacizumab**
- **Niraparib**
- **Other treatments**

This information is unavailable

08 December 2023

**Q5. Does your trust participate in any clinical trials for the treatment of ovarian cancer? If so, please provide the name of each trial along with the number of patients taking part.**

<b>Ovarian Cancer Trial/Study Activity Nov 23</b>			
<b>IMPRESS</b>	IMproving outcomes for ovarian cancer Patients by Refining Evidenced based tools that drive Surgical Standardisation	312	Closed
<b>MONITOR</b>	Multi-centre Observational study of maintenance Niraparib in Treatment of Ovarian Cancer: UK routine clinical practice experience	20	Local target met
<b>PROTECTOR</b>	Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal	46	Open
<b>RaNGO</b>	Rare Neoplasms of Gynaecological Origin	33	Closed
<b>TARGET-National</b>	Tumour Characterisation to Guide Experimental Targeted Therapy–National	2	Open

Please note:

We are unable to provide an exact figure where numbers are very low, <5. To provide this level of information would reduce numbers to discoverable limits where the patients could be identifiable. This is because many of these drugs are high cost and prescribed on a named patient basis. Pharmaceutical companies, would be aware of this.

This is exempt from release under section 40(2) Personal Information relating to a third party, of the FOI Act.

Disclosure would constitute a breach of the principles of the Data Protection Act 2018.